Browsing by Author "Sullivan, Keith M"

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.

Green, Michael MB; Chao, Nelson; Chhabra, Saurabh; Corbet, Kelly; Gasparetto, Cristina; Horwitz, Ari; Li, Zhiguo; ... (18 authors) (J Hematol Oncol, 2018-03-04)

BACKGROUND: The binding of CXCR4 with its ligand (stromal-derived factor-1) maintains hematopoietic stem/progenitor cells (HSPCs) in a quiescent state. We hypothesized that blocking CXCR4/SDF-1 interaction after hematopoietic ...

Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement.

Sullivan, Keith M; Shah, Ankoor; Sarantopoulos, Stefanie; Furst, Daniel E (Arthritis Rheumatol, 2016-10)

Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation.

Sullivan, Keith M; Majhail, Navneet S; Bredeson, Christopher; Carpenter, Paul A; Chatterjee, Soumya; Crofford, Leslie J; Georges, George E; ... (13 authors) (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018-06-25)

Systemic sclerosis is a progressive inflammatory disease that is frequently fatal and has limited treatment options. High-dose chemotherapy with autologous hematopoietic cell transplantation (AHCT) has been evaluated as ...

Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.

Horwitz, Mitchell E; Chao, Nelson J; Rizzieri, David A; Long, Gwynn D; Sullivan, Keith M; Gasparetto, Cristina; Chute, John P; ... (23 authors) (The Journal of clinical investigation, 2014-07)

<h4>Background</h4>Delayed hematopoietic recovery is a major drawback of umbilical cord blood (UCB) transplantation. Transplantation of ex vivo-expanded UCB shortens time to hematopoietic recovery, but long-term, robust ...